Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2004 Aug 01;1428:1300-8. doi: 10.1038/sj.bjp.0705879.
Show Gene links
Show Anatomy links
Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.
Schram G
,
Zhang L
,
Derakhchan K
,
Ehrlich JR
,
Belardinelli L
,
Nattel S
.
???displayArticle.abstract???
Ranolazine is a novel anti-ischemic drug that prolongs the QT interval. To evaluate the potential mechanisms and consequences, we studied: (i) Ranolazine's effects on HERG and IsK currents in Xenopus oocytes with two-electrode voltage clamp; (ii) effects of ranolazine, compared to d-sotalol, on effective refractory period (ERP), QT interval and ventricular rhythm in a dog model of acquired long QT syndrome; and (iii) effects on selected native currents in canine atrial myocytes with whole-cell patch-clamp technique. Ranolazine inhibited HERG and IsK currents with different potencies. HERG was inhibited with an IC(50) of 106 micromol l(-1), whereas the IC(50) for IsK was 1.7 mmol l(-1). d-Sotalol caused reverse use-dependent ERP and QT interval prolongation, whereas ranolazine produced modest, nonsignificant increases that plateaued at submaximal doses. Neither drug affected QRS duration. d-Sotalol had clear proarrhythmic effects, with all d-sotalol-treated dogs developing torsades de pointes (TdP) ventricular tachyarrhythmias, of which they ultimately died. In contrast, ranolazine did not generate TdP. Effects on I(Kr) and I(Ks) were similar to those on HERG and IsK. Ranolazine blocked I(Ca) with an IC(50) of approximately 300 micromol l(-1). I(Na) was unaffected. We conclude that ranolazine inhibits I(Kr) by blocking HERG currents, inhibits I(Ca) at slightly larger concentrations, and has modest and self-limited effects on the QT interval. Unlike d-sotalol, ranolazine does not cause TdP in a dog model. The greater safety of ranolazine may be due to its ability to inhibit I(Ca) at concentrations only slightly larger than those that inhibit I(Kr), thus producing offsetting effects on repolarization.
Abbott,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
1999, Pubmed,
Xenbase
Abbott,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
1999,
Pubmed
,
Xenbase
Allely,
The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog.
1988,
Pubmed
Allely,
Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion.
1990,
Pubmed
Allen,
Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes.
1996,
Pubmed
Barhanin,
K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current.
1996,
Pubmed
,
Xenbase
Biliczki,
Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve.
2002,
Pubmed
Black,
Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion.
1994,
Pubmed
Carmeliet,
Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers.
1985,
Pubmed
Chaitman,
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
2004,
Pubmed
Chaitman,
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
2004,
Pubmed
Chandler,
Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure.
2002,
Pubmed
Clarke,
Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase.
1993,
Pubmed
Clarke,
Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism.
1996,
Pubmed
Cocco,
Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
1992,
Pubmed
Conti,
Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina.
2003,
Pubmed
Courtemanche,
Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model.
1998,
Pubmed
Derakhchan,
Polymorphic ventricular tachycardias induced by D-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry.
1998,
Pubmed
Feng,
Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes.
1997,
Pubmed
Ferrari,
Metabolic modulation and optimization of energy consumption in heart failure.
2003,
Pubmed
Gralinski,
Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.
1994,
Pubmed
Jain,
Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
1990,
Pubmed
Keating,
Molecular and cellular mechanisms of cardiac arrhythmias.
2001,
Pubmed
Li,
Effects of experimental heart failure on atrial cellular and ionic electrophysiology.
2000,
Pubmed
Li,
Transmembrane ICa contributes to rate-dependent changes of action potentials in human ventricular myocytes.
1999,
Pubmed
Li,
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes.
1996,
Pubmed
Louis,
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure.
2002,
Pubmed
Lu,
Effects of the diuretic agent indapamide on Na+, transient outward, and delayed rectifier currents in canine atrial myocytes.
1998,
Pubmed
McCormack,
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.
1996,
Pubmed
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Nattel,
Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms.
1988,
Pubmed
Nattel,
Recent advances in understanding the pharmacology of amiodarone.
1988,
Pubmed
Pepine,
A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
1999,
Pubmed
Roden,
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.
1996,
Pubmed
Sanguinetti,
Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.
1996,
Pubmed
,
Xenbase
Sanguinetti,
Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia.
1999,
Pubmed
Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed
Sanguinetti,
Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells.
1991,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Thadani,
Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
1994,
Pubmed
Trudeau,
HERG, a human inward rectifier in the voltage-gated potassium channel family.
1995,
Pubmed
Weerapura,
A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?
2002,
Pubmed
,
Xenbase
Wu,
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
2004,
Pubmed
Zacharowski,
Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.
2001,
Pubmed
Zhang,
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
1999,
Pubmed